Diffuse Large B-Cell Lymphoma NewsLatest News On Diffuse Large B-Cell Lymphoma DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo7/24/2025 6:25 AM Drug Combo Outpaces Standard Chemo in R/R LBCL7/8/2025 11:48 PM DLBCL Debate: Is Pola-R-CHP a Suitable Standard for All?7/8/2025 12:24 PM Multitasking ctDNA Helps Guide Lymphoma Treatment6/22/2025 11:32 PM Can Tumor Patterns Predict Lymphoma Treatment Success?6/19/2025 2:45 AM Pola-R-GemOx Boosts Survival in R/R DLBCL6/15/2025 11:45 AM Can New Biomarker Help Identify High-Risk DLBCL Patients?6/1/2025 12:57 PM FDA Advisory: Daratumumab Wins for Smoldering Myeloma Glofitamab Loses for Early Line R/R Diffuse Large B-Cell Lymphoma5/22/2025 8:14 AM Can Two Targets Better Fight B-Cell Lymphoma?5/16/2025 4:50 AM Lymphoma: Muscle Mass May Presage CAR T Outcomes5/7/2025 7:45 AM
